Tumor necrosis factor superfamily ligands (TNF)

IW927 is a potent small molecule antagonist that blocks the binding of TNF-α to TNFRc1 with an IC 50 value of 50 nM and disrupts TNFα-induced IκB phosphorylation with an IC 50 value of 600 nM.Form:Solid

KR-33493 is a potent inhibitor of Fas-mediated cell death ( FAF1 ).In VivoBody weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups

KR-33493 is a potent inhibitor of Fas-mediated cell death ( FAF1 ).In VivoBody weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups

KR-33493 is a potent inhibitor of Fas-mediated cell death ( FAF1 ).In VivoBody weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups

KR-33493 is a potent inhibitor of Fas-mediated cell death ( FAF1 ).In VivoBody weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups

KR-33493 is a potent inhibitor of Fas-mediated cell death ( FAF1 ).In VivoBody weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups

KR-33493 is a potent inhibitor of Fas-mediated cell death ( FAF1 ).In VivoBody weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups

LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to

LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to

Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC 50 =12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2

Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC 50 =12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2

LY 303511 hydrochloride is a structural analogue of LY294002. LY303511 does not inhibit PI3K . LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K + currents (IC 50 =64.6±9.1 μM) in MIN6 insulinoma